ATE451835T1 - Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae - Google Patents

Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Info

Publication number
ATE451835T1
ATE451835T1 AT00965349T AT00965349T ATE451835T1 AT E451835 T1 ATE451835 T1 AT E451835T1 AT 00965349 T AT00965349 T AT 00965349T AT 00965349 T AT00965349 T AT 00965349T AT E451835 T1 ATE451835 T1 AT E451835T1
Authority
AT
Austria
Prior art keywords
patient
compositions
viruses
protein
therapeutic methods
Prior art date
Application number
AT00965349T
Other languages
English (en)
Inventor
Stephen J Russell
Roberto Cattaneo
Kah-Whye Peng
Urs Schneider
Anthea L Murphy
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE451835T1 publication Critical patent/ATE451835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00965349T 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae ATE451835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15587399P 1999-09-24 1999-09-24
PCT/US2000/026116 WO2001020989A1 (en) 1999-09-22 2000-09-22 Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family

Publications (1)

Publication Number Publication Date
ATE451835T1 true ATE451835T1 (de) 2010-01-15

Family

ID=22557120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965349T ATE451835T1 (de) 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Country Status (6)

Country Link
EP (1) EP1217891B1 (de)
AT (1) ATE451835T1 (de)
AU (1) AU7607900A (de)
CA (1) CA2383276A1 (de)
DE (1) DE60043547D1 (de)
WO (1) WO2001020989A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241617B2 (en) 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
AU2003234775A1 (en) 2002-04-30 2003-11-17 Dnavec Research Inc. Vector with modified protease-dependent tropism
EP1549672B1 (de) * 2002-05-03 2010-09-01 Mayo Foundation For Medical Education And Research Reduzierter slam abhängiger zell eintritt
WO2004064785A2 (en) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
WO2004111249A2 (en) * 2003-06-13 2004-12-23 Polymun Scientific Immunbiologische Forschung Gmbh Protein constructs containing caspase recognition sites
ATE420160T1 (de) 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
CA2545024A1 (en) * 2003-11-24 2005-06-02 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins
EP1715048A4 (de) * 2004-01-22 2007-02-07 Dnavec Research Inc Verfahren zur herstellung eines virusvektors
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
AU2006237613A1 (en) 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
EP2097517B1 (de) 2006-10-16 2014-06-04 Genelux Corporation Rekombinantes Lister-Stamm Vaccinia Virus kodierend für einen einzelkettigen anti-VEGF Antikörper
AU2008299020A1 (en) * 2007-09-11 2009-03-19 Sapphire Energy, Inc. Molecule production by photosynthetic organisms
EP2085092A1 (de) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen
EP2085479A1 (de) 2008-01-31 2009-08-05 Institut Pasteur Reverse Genetik von Negativstrang-RNA-Viren in Hefe
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (de) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimäre newcastle-krankheitsviren und verwendungen davon
ES2492691T3 (es) * 2010-06-10 2014-09-10 Intervet International B.V. Composición antitumoral
KR20140128966A (ko) * 2012-01-26 2014-11-06 라이프 테크놀로지스 코포레이션 바이러스의 감염성을 증가시키는 방법
AU2013212068B2 (en) 2012-01-26 2018-02-15 Life Technologies Corporation Methods for increasing the infectivity of viruses
EP2968525A4 (de) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai Morbus-newcastle-viren und verwendungen davon
HUE042382T2 (hu) 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
EP3110443A4 (de) 2014-02-27 2017-11-15 Viralytics Limited Kombinationsverfahren zur behandlung von krebs
EP3242939A4 (de) * 2015-01-05 2018-10-17 Seagull BioSolutions Pvt. Ltd. Dna-moleküle zur herstellung individuell gestalteter replizierender und nicht-replizierenden, negativsträngiger rna-viren und verwendungen davon
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3625349B1 (de) 2017-05-16 2024-08-28 Mayo Foundation for Medical Education and Research Modifizierte viren
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2025088124A1 (en) 2023-10-27 2025-05-01 Boehringer Ingelheim International Gmbh Novel assay for determining infectious virus titer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514368D0 (en) 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
US6264957B1 (en) * 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences

Also Published As

Publication number Publication date
EP1217891A1 (de) 2002-07-03
EP1217891B1 (de) 2009-12-16
CA2383276A1 (en) 2001-03-29
AU7607900A (en) 2001-04-24
EP1217891A4 (de) 2004-05-12
DE60043547D1 (de) 2010-01-28
WO2001020989A9 (en) 2002-10-03
WO2001020989A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
Sambhi et al. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.
Merigan et al. Purification and characterization of vertebrate interferons
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
DK1266006T3 (da) Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
RU95115239A (ru) Аналог эритропоэтина
RU2001117230A (ru) Пептиды, ингибирующие трансформирующий фактор роста tgf$$$1
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
JP2014509197A (ja) 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
GB2161487A (en) Interferon epsilon
DE69627526D1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
Hofacre et al. Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models
Ahmed et al. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
Norton et al. Expression of secreted platelet-derived growth factor-B by recombinant nonreplicating and noncytopathic vaccinia virus
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties